Search Site

Michio Hirano, MD

  • Professor of Neurology
  • Chief, Division of Neuromuscular Disorders
  • Director, H. Houston Merritt Clinical Research Center
  • Medical Director, Laboratory of Molecular Genetics/Laboratory of Metabolic and Mitochondrial Disease
Michio Hirano, MD

Dr. Hirano received his B.A. from Harvard College and M.D. from the Albert Einstein College of Medicine. At the Columbia University Medical Center (CUMC), he did his neurology residency training and a post-doctoral fellowship in neuromuscular genetics under Drs. Salvatore DiMauro and Eric Schon.

Currently, Dr. Hirano serves as Chief of the Neuromuscular Division, Co-Director of the CUMC Muscular Dystrophy Association clinic, and Director of the H. Houston Merritt Center for Muscular Dystrophy and Related Diseases. He evaluated patients with myopathies and other neuromuscular disorders.

Dr. Hirano's research focuses on mitochondrial diseases and genetic myopathies. He is participating in the clinical trial of idebenone for MELAS patients. Together with Co-Principal Investigators, Drs. Salvatore DiMauro and J.L.P (Seamus) Thompson, Dr. Hirano is co-directing the North American Mitochondrial Disease Consortium (NAMDC).

Dr. Hirano serves on the NIH Therapeutic Approaches to Genetic Diseases (TAG) study section, Medical Advisory Committee (MAC) of the Muscular Dystrophy Association, and Scientific Advisory Board of the United Mitochondrial Disease Foundation.

Departmental Appointments

  • Department of Neurology
    Division of Neuromuscular Medicine

Education & Training

  • Albert Einstein College of Medicine of Yeshiva University
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

Centers/Institutes/Programs

  • ALS/PLS (Amyotrophic/Primary Lateral Sclerosis) Center
  • H. Houston Merritt Clinical Research Center
  • Laboratory of Molecular Genetics/Laboratory of Metabolic and Mitochondrial Disease

Contact Info

  • Office Phone: 212-305-1319

Honors & Awards

America's Best Doctors

Elected member of the American Neurological Association

Elected Fellow of the American Academy of Neurology

Research Interests

  • Molecular biology of neuromuscular disorders. Positional cloning techniques applied to autosomal disorders affecting the mitochondrial genome. Investigations of mutations of mitochondrial DNA in human cardiomyopathies.

NIH Grants

  • ADULT MDA AND MDA/ALS CARE CENTERS AT COLUMBIA MEDICAL UNIVERSITY MEDICAL CENTER (Private)

    Jan 1 2017 - Dec 31 2019

    NAMDC: OVERALL RESEARCH PLAN (Federal Gov)

    Sep 1 2014 - Aug 31 2019

    MITOCHONDRIAL ENCEPHALOMYOPATHIES: APPROACHES TO TREATMENT (Federal Gov)

    Sep 30 2014 - May 31 2019

    DEVELOPMENT OF A COMPLETE PIPELINE FOR MELAS DRUG DISCOVERY (Private)

    Dec 17 2015 - Dec 16 2018

    AMERICAN MITOCHONDRIAL DISEASE CONSORTIUM PATIENT REGISTRY AND BIOREPOSITORY (Private)

    Jul 1 2011 - Jun 30 2017

    TREATMENT POTENTIAL OF SELECTIVE HDAC6 INHIBITORS IN PAINFUL PERIPHERAL NEUROPATHY (Private)

    Jan 1 2016 - Jul 31 2016

    NEW YORK COLUMBIA COLLABORATIVE SPOTRIAS (Federal Gov)

    Aug 1 2010 - Jul 31 2016

    AMERICAN MITOCHONDRIAL DISEASE CONSORTIUM PATIENT REGISTRY AND BIOREPOSITORY (Private)

    Jul 1 2011 - Jun 30 2016

    THE USE OF EPI-743 IN ACUTELY III PATIENTS WITH INHERITED MITOCHONDRIAL RESPIRATORY CHAIN DISEASE WITHIN 90 DAYS OF (P&S Industry Clinical Trial)

    Mar 9 2011 - Mar 9 2016

    MITOCHONDRIAL ENCEPHALOMYOPATHIES AND MENTAL RETARDATION (Federal Gov)

    Dec 1 1996 - Feb 29 2016

    MOLECULAR PATHOGENESIS AND TREATMENT OF MNGIE (Federal Gov)

    Apr 1 2010 - Jan 31 2016

    SMA FOUNDATION CENTER GRANT (Private)

    Jul 1 2015 - Dec 31 2015

    DEVELOPMENT OF A COMPLETE PIPELINE FOR MELAS DRUG DISCOVERY (Private)

    Jan 1 2014 - Dec 31 2015

    METABOLITE BIOMARKER DISCOVERY IN MELAS (Private)

    Jan 1 2014 - Dec 31 2015

    MOLECULAR BYPASS THERAPY FOR TK2 DEFICIENCY (Private)

    Aug 1 2012 - Jul 31 2015

    EPI743 TREATMENT OF ONE MITOCHONDRIAL DISEASE PATIENT (P&S Industry Clinical Trial)

    Nov 16 2009 - Nov 16 2014

    DEVELOPMENT OF A MITOCHONDRIAL DISEASE PATIENT REGISTRY (Private)

    Nov 1 2012 - Oct 31 2014

    MELTIMI STUDY(EVALUATION OF INDEBENONE TREATMENT IN PATIENTS WITH MITOCHONDRIAL DISORDERS (P&S Industry Clinical Trial)

    Jul 1 2009 - Jul 1 2014

    IDENTIFYING MITOCHONDRIAL DNA POLYMORPHISMS THAT CONFER GENETIC SUSCEPTIBILITY TO ZYVOX TOXICITY (Private)

    Jul 1 2006 - Mar 31 2014

    MOLECULAR PATHOGENESIS OF COENZYME Q10 DEFICIENCY (Federal Gov)

    Jan 10 2008 - Dec 31 2013

    MOLECULAR PATHOGENESIS OF SCAPULOPERONEAL MYOPATHY DUE TO FH L1 MUTATIONS (Private)

    Jan 1 2009 - Feb 29 2012

    MOLECULAR PATHOGENESIS OF SCAPULOPERONEAL MYOPATHY DUE TO FH L1 MUTATIONS (Private)

    Jan 1 2009 - Feb 29 2012

    HARLEM HOSPITAL AFFILIATION CONTRACT - GENERAL (NY Local Gov)

    Jul 1 2005 - Jun 30 2008